PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Drug Interaction Study Between Raltegravir And UK-453,061
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2008-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00784420
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
Phase 2
Terminated
- Conditions
- Endometriosis
- Interventions
- Biological: TanezumabDrug: Placebo
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00784693
- Locations
- 🇺🇸
Women's Healthcare Group, Overland Park, Kansas, United States
🇺🇸N.E.C.C.R, Fall River LLC, Fall River, Massachusetts, United States
🇺🇸Mount Vernon Clinical Research, Atlanta, Georgia, United States
Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy
Completed
- Conditions
- Breast Neoplasms
- Interventions
- Other: Aromatase inhibitors
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 344
- Registration Number
- NCT00784888
- Locations
- 🇹🇷
Pfizer Investigational Site, Trabzon, Turkey
A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.
Phase 1
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 327
- Registration Number
- NCT00784719
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: suspension IRDrug: CR 1Drug: CR 2Drug: CR 3
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00782600
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT00783328
- Locations
- 🇯🇵
Pfizer Investigational Site, Sunto-gun, Shizuoka, Japan
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2010-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00783406
- Locations
- 🇩🇪
Pfizer Investigational Site, Wiesbaden, Germany
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00783484
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Cumulative Irritation Test
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT00781664
- Locations
- 🇺🇸
The Education and Research Foundation, Inc., Lynchburg, Virginia, United States
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
Terminated
- Conditions
- Breast Neoplasms
- Interventions
- Other: Aromasin
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT00776659
- Locations
- 🇮🇳
Pfizer Investigational Site, Lucknow, Uttar Pradesh, India
© Copyright 2025. All Rights Reserved by MedPath